Loading
Ruxolitinib was the first JAK inhibitor: it shrinks the spleen and relieves symptoms in myelofibrosis and controls blood counts in polycythaemia vera, without eliminating the disease clone.
COMFORT-I/II (2011) showed spleen volume and symptom benefit versus placebo/best available therapy with a later-demonstrated survival advantage; RESPONSE (2014) established it in hydroxyurea-resistant PV. Also approved in acute and chronic graft-versus-host disease (REACH2/3). Anaemia, thrombocytopenia, infections and a discontinuation syndrome are the main issues.
ATP-competitive inhibition of JAK1 and JAK2, dampening JAK-STAT signalling regardless of JAK2/CALR/MPL driver. Connects to JAK2 and JAK1.
1.Ruxolitinib slips into a pocket on JAK2.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). Jakafi is a Part D specialty drug; generic entry is not expected before 2028.
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy.
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
Sources: NICE TA386 · SMC advice: ruxolitinib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 2011 | Intermediate/high-risk myelofibrosis |
| US | 2014 | Polycythaemia vera after hydroxyurea |
| US | 2019 | Steroid-refractory acute GVHD |
| US | 2021 | Chronic GVHD after failure of 1-2 lines |
| EU | 2012 | Myelofibrosis |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
With COMFORT-I, the evidence for ruxolitinib as the first approved treatment for myelofibrosis and for JAK inhibition as the standard for spleen and symptom control.
Query for this drug: (TITLE:"Ruxolitinib" OR ABSTRACT:"Ruxolitinib" OR TITLE:"Jakafi" OR ABSTRACT:"Jakafi" OR TITLE:"Jakavi" OR ABSTRACT:"Jakavi") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ruxolitinib, not a curated reading list.
Shares Post-PV myelofibrosis (spent phase), DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, JAK1.
Shares DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, JAK1, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis.
Shares Aquagenic pruritus, JAK2 V617F, Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission, Essential thrombocythaemia (ET).
Shares A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis), DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores), COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, JAK2.
Shares Pipobroman, MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden, Essential thrombocythaemia (ET), Polycythaemia vera (PV).
Shares T-cell large granular lymphocytic leukaemia, MPL (thrombopoietin receptor), JAK1, JAK2.
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors.
Shares When steroids fail: ruxolitinib for steroid-refractory GvHD, Chronic graft-versus-host disease, Graft-versus-host disease (GVHD) and graft-versus-leukaemia, Allogeneic stem cell transplantation.